Pharmaceutical Technology Europe-09-01-2012

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

Experts share insight on facility design and operations for high-potency manufacturing.

Following an inquiry in 2009 that suggested the launch of various generic drugs was being delayed by anticompetitive business practices, the European Commission (EC) has been closely monitoring deals for potential breaches of the EU's antitrust rules.

Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?

There is no harmonized guidance on pre-use integrity testing of sterilizing filters, prompting discussion among users as to whether such testing is necessary.

Rob Blanchard and Clive Roberts discuss the issues surrounding tablet sticking.

Big Pharma Placed in Malpractice Spotlight and other news from across the globe.

Click the title above to open the Pharmaceutical Technology Europe September 2012 issue in an interactive PDF format.